Eli Lilly and Company (LLY) 72.30 $LLY
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:30PM CDT
CAM: 49.02 (+0.36), BBT: 38.87 (+0.21), LAZ: 56.56 (-0.08), JAH: 51.68 (-0.16), ASPS: 18.07 (+1.32), HSY: 98.33 (+0.31), CAB: 53.76 (-0.12), CFX: 48.68 (+0.12), FAF: 36.74 (+0.57), HP: 73.53 (+1.48), KKR: 23.37 (+0.21), AEP: 56.14 (+0.17), DNKN: 47.72 (+0.21), CLFD: 15.63 (+0.19), DAN: 21.57 (+0.18), ABBV: 64.52 (+0.91), CSL: 94.86 (+0.78), CAT: 84.87 (+0.95), BHE: 24.51 (-0.19), AVT: 45.49 (+0.28), IR: 67.49 (+0.29), COR: 48.82 (-0.57), ALK: 64.31 (-0.62), COL: 96.55 (+0.45), BKU: 33.64 (+0.12), BCC: 38.42 (-0.13), MJN: 98.92 (-1.00), IQNT: 18.03 (+0.28), ERIC: 12.70 (-0.09), DGX: 76.29 (+0.08), ALXN: 188.19 (+1.41), DOW: 50.02 (+0.37), DST: 116.35 (+0.44), MDP: 52.99 (-0.41), MMM: 164.67 (+0.67), GRA: 97.10 (+0.03), FCX: 20.57 (+0.34), CLI: 18.28 (-0.01), DHR: 85.25 (+0.05), FNB: 13.21 (+0.10), LUV: 42.85 (-0.18), DPS: 78.81 (-0.38), IVC: 19.80 (+0.24), GMT: 59.92 (+0.42), JNS: 17.93 (unch), DPZ: 99.80 (+0.40), DLX: 69.57 (+0.47), CMS: 35.07 (+0.15), LTM: 71.60 (+0.17), MDSO: 47.66 (+0.43), LLY: 72.30 (+0.09), BMS: 44.00 (+0.09), EQT: 87.29 (+0.85), MHO: 23.74 (-0.25), BTU: 4.87 (+0.06), GPK: 14.24 (+0.15), BAX: 70.38 (+0.33), EQM: 83.89 (+0.08), BEAV: 63.43 (-0.01), GM: 37.16 (unch), HUB.B: 110.19 (-0.19), JCI: 51.33 (+0.30)
Biotech First-Quarter Venture Haul Unprecedented Since Crash
EP Vantage - Seeking Alpha - Wed Apr 22, 11:29AM CDT
The $1.9bn in venture cash raised by biotech companies in the first three months of 2015 makes this period the strongest first quarter in at least eight years- and suggests that investors continue to believe that the public markets will welcome...
ADRO: 38.17 (-0.50), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), LLY: 72.30 (+0.09)
Lilly reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:09AM CDT
LLY: 72.30 (+0.09)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)
Deciphera Pharmaceuticals Presents Data Highlighting Kinase Inhibitor Pipeline including Proprietary and Partnered Programs at AACR 2015 Annual Meeting
Business Wire - Wed Apr 22, 7:00AM CDT
Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that preclinical data on the company's growing pipeline of next generation kinase inhibitors were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015. The presentations include data on Deciphera's most advanced proprietary drug candidates including altiratinib, a potent and balanced inhibitor of MET/TRK/TIE2 and VEGFR2 kinases and rebastinib, a TIE2 inhibitor, and on the Company's work with Eli Lilly and Company on pan-RAF inhibitors.
LLY: 72.30 (+0.09)
Fitch Affirms Eli Lilly's IDR at 'A'; Outlook Stable
Business Wire - Tue Apr 21, 4:34PM CDT
Fitch Ratings affirms Eli Lilly & Co. Inc.'s (Lilly) long-term Issuer Default Rating (IDR) at 'A'. In addition, Fitch affirms the company's short-term IDR at 'F1'. The Rating Outlook is Stable. The rating actions apply to roughly $7.6 billion of debt outstanding at Dec. 31, 2014. A full list of the rating actions is provided at the end of this release.
LLY: 72.30 (+0.09)
Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:12PM CDT
New products and continued growth of a few core products could help Eli Lilly (LLY) beat earnings expectations in 1Q despite generics and currency headwinds.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), LLY: 72.30 (+0.09), NVS: 103.45 (-0.62)
OncoMed Down on Phase Ib Lung Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:25PM CDT
OncoMed Pharmaceuticals Inc. (OMED) announced discouraging new data from a phase Ib study on demcizumab for first-line advanced non-small cell lung cancer.
OMED: 25.81 (-0.32), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), LLY: 72.30 (+0.09)
Lilly's ixekizumab successful in Phase 3 psoriatic arthritis trial
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:19AM CDT
LLY: 72.30 (+0.09)
Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015
PR Newswire - Mon Apr 20, 8:00AM CDT
Eli Lilly and Company (NYSE: LLY) will present early stage data from several targeted cancer therapies, reflecting Lilly's diverse oncology pipeline, during the American Association for Cancer Research (AACR) Annual Meeting 2015, held April 18-22 in Philadelphia, Pa.
LLY: 72.30 (+0.09)
Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis
PR Newswire - Mon Apr 20, 7:00AM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a 20 percent reduction in disease signs and symptoms as defined by the American College of Rheumatology response criteria. During the 24-week, Phase 3 study, titled SPIRIT-P1, patients who were naïve to biologic disease-modifying antirheumatic drugs (bDMARD) were treated with one of two different ixekizumab dosing regimens or placebo. In both dosing regimens, ixekizumab-treated patients demonstrated significant improvements versus placebo in signs and symptoms of active PsA.
LLY: 72.30 (+0.09)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Chasing High Dividend Growth Rates For Lower Total Returns
Kurtis Hemmerling - at Seeking Alpha - Mon Apr 20, 5:24AM CDT
RF: 9.73 (+0.15), HSY: 98.33 (+0.31), GPC: 93.02 (+0.57), CAG: 37.52 (-0.09), ED: 61.64 (+0.17), SYY: 37.63 (+0.03), RRD: 19.55 (+0.07), GWW: 243.45 (+0.44), TGT: 81.34 (+0.09), LOW: 73.07 (-0.17), BCR: 175.09 (+0.24), PFE: 34.93 (+0.04), VFC: 73.91 (-0.42), FDO: 79.25 (-0.09), MHFI: 104.25 (+0.69), MO: 52.12 (+0.02), WBA: 87.02 (-0.07), ADP: 85.31 (+0.21), ADM: 48.10 (+0.16), SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), MCD: 97.84 (+2.97), DOV: 71.89 (-0.04), CTL: 36.27 (-0.03), MMM: 164.67 (+0.67), TE: 19.40 (unch), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), HBAN: 11.03 (-0.14), KMB: 111.85 (-1.30), AON: 97.20 (+0.10), CB: 99.30 (-0.44), KEY: 14.34 (+0.16), K: 63.98 (+0.12), PEP: 97.28 (+0.50), SWK: 98.11 (+1.03), JNJ: 100.43 (+0.13), AVY: 51.78 (+0.28), CMA: 46.05 (+0.62), PPG: 226.40 (-0.65), KO: 41.31 (+0.53), XEL: 34.31 (+0.03), ABT: 48.35 (+1.23), NUE: 46.82 (+0.01), SVU: 11.01 (-0.10), EMR: 58.15 (-0.07), LEG: 44.32 (unch), LLY: 72.30 (+0.09), ITW: 94.44 (+0.02), PLL: 97.75 (-0.81), USB: 42.83 (+0.33), GCI: 35.17 (-0.83), PG: 83.09 (+0.01), JCI: 51.33 (+0.30)
After Yesterday's Decline of 1.39%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Fri Apr 17, 4:23PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $71.96 to a high of $73.20. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $73.10 on volume of 4.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 72.30 (+0.09)
SmarTrend Watching for Potential Rebound in Shares of Eli Lilly After 1.39% Loss
Comtex SmarTrend(R) - Fri Apr 17, 4:22PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $71.96 to a high of $73.20. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $73.10 on volume of 4.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 72.30 (+0.09)
Bristol-Myers to Transfer Certain Erbitux Rights to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:45PM CDT
Bristol-Myers announced its intention to transfer its rights to Erbitux in North America to Eli Lilly and Company.
VRX: 206.93 (-3.92), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
Bristol-Myers Squibb Company announces transfer of full commercialisation rights to Eli Lilly and Company for Erbitux (cetuximab)
M2 - Fri Apr 17, 6:15AM CDT
Biopharmaceutical products company Bristol-Myers Squibb Company (NYSE:BMY) declared on Thursday an agreement to transfer the rights to Erbitux (cetuximab) in North America, including the US, Canada and Puerto Rico, to Eli Lilly and Company (NYSE:LLY).
LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:04PM CDT
AstraZeneca's (AZN) Onglyza and Kombiglyze XR labels have been recommended to include new safety information as per an FDA panel.
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), LLY: 72.30 (+0.09)
Bristol-Myers transfers Erbitux to Eli Lilly in North America
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:53AM CDT
LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
Lilly, Bristol-Myers Squibb Restructure Erbitux(R) (cetuximab) Collaboration in North America
Business Wire - Thu Apr 16, 11:15AM CDT
Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux(R) (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers Squibb to Lilly. Rights include, but are not limited to, full commercialization and manufacturing operational responsibilities. The companies' decision comes after a 14-year successful collaboration, which includes Lilly's wholly-owned subsidiary ImClone LLC. Bristol-Myers Squibb and Lilly will work closely to ensure a smooth transition on this important product for patients with certain advanced colorectal and head and neck cancers.
LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 4:30PM CDT
CAM: 49.02 (+0.36), BBT: 38.87 (+0.21), LAZ: 56.56 (-0.08), JAH: 51.68 (-0.16), ASPS: 18.07 (+1.32), HSY: 98.33 (+0.31), CAB: 53.76 (-0.12), CFX: 48.68 (+0.12), FAF: 36.74 (+0.57), HP: 73.53 (+1.48), KKR: 23.37 (+0.21), AEP: 56.14 (+0.17), DNKN: 47.72 (+0.21), CLFD: 15.63 (+0.19), DAN: 21.57 (+0.18), ABBV: 64.52 (+0.91), CSL: 94.86 (+0.78), CAT: 84.87 (+0.95), BHE: 24.51 (-0.19), AVT: 45.49 (+0.28), IR: 67.49 (+0.29), COR: 48.82 (-0.57), ALK: 64.31 (-0.62), COL: 96.55 (+0.45), BKU: 33.64 (+0.12), BCC: 38.42 (-0.13), MJN: 98.92 (-1.00), IQNT: 18.03 (+0.28), ERIC: 12.70 (-0.09), DGX: 76.29 (+0.08), ALXN: 188.19 (+1.41), DOW: 50.02 (+0.37), DST: 116.35 (+0.44), MDP: 52.99 (-0.41), MMM: 164.67 (+0.67), GRA: 97.10 (+0.03), FCX: 20.57 (+0.34), CLI: 18.28 (-0.01), DHR: 85.25 (+0.05), FNB: 13.21 (+0.10), LUV: 42.85 (-0.18), DPS: 78.81 (-0.38), IVC: 19.80 (+0.24), GMT: 59.92 (+0.42), JNS: 17.93 (unch), DPZ: 99.80 (+0.40), DLX: 69.57 (+0.47), CMS: 35.07 (+0.15), LTM: 71.60 (+0.17), MDSO: 47.66 (+0.43), LLY: 72.30 (+0.09), BMS: 44.00 (+0.09), EQT: 87.29 (+0.85), MHO: 23.74 (-0.25), BTU: 4.87 (+0.06), GPK: 14.24 (+0.15), BAX: 70.38 (+0.33), EQM: 83.89 (+0.08), BEAV: 63.43 (-0.01), GM: 37.16 (unch), HUB.B: 110.19 (-0.19), JCI: 51.33 (+0.30)
Biotech First-Quarter Venture Haul Unprecedented Since Crash
EP Vantage - Seeking Alpha - Wed Apr 22, 11:29AM CDT
The $1.9bn in venture cash raised by biotech companies in the first three months of 2015 makes this period the strongest first quarter in at least eight years- and suggests that investors continue to believe that the public markets will welcome...
ADRO: 38.17 (-0.50), XBI: 232.63 (-0.32), IBB: 363.84 (-0.66), LLY: 72.30 (+0.09)
Lilly reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:09AM CDT
LLY: 72.30 (+0.09)
A Discussion Of Amgen's Q1 Results, With Updates On Its Pipeline
DoctoRx - at Seeking Alpha - Wed Apr 22, 8:28AM CDT
PFE: 34.93 (+0.04), AMGN: 169.10 (+0.64), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21), SNY: 51.59 (+0.03), REGN: 472.63 (+9.41), HSP: 87.80 (+0.04), CELG: 115.54 (+0.72)
Deciphera Pharmaceuticals Presents Data Highlighting Kinase Inhibitor Pipeline including Proprietary and Partnered Programs at AACR 2015 Annual Meeting
Business Wire - Wed Apr 22, 7:00AM CDT
Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that preclinical data on the company's growing pipeline of next generation kinase inhibitors were presented at the American Association for Cancer Research (AACR) Annual Meeting 2015. The presentations include data on Deciphera's most advanced proprietary drug candidates including altiratinib, a potent and balanced inhibitor of MET/TRK/TIE2 and VEGFR2 kinases and rebastinib, a TIE2 inhibitor, and on the Company's work with Eli Lilly and Company on pan-RAF inhibitors.
LLY: 72.30 (+0.09)
Fitch Affirms Eli Lilly's IDR at 'A'; Outlook Stable
Business Wire - Tue Apr 21, 4:34PM CDT
Fitch Ratings affirms Eli Lilly & Co. Inc.'s (Lilly) long-term Issuer Default Rating (IDR) at 'A'. In addition, Fitch affirms the company's short-term IDR at 'F1'. The Rating Outlook is Stable. The rating actions apply to roughly $7.6 billion of debt outstanding at Dec. 31, 2014. A full list of the rating actions is provided at the end of this release.
LLY: 72.30 (+0.09)
Will Eli Lilly (LLY) Beat Earnings in 1Q Despite Generics? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:12PM CDT
New products and continued growth of a few core products could help Eli Lilly (LLY) beat earnings expectations in 1Q despite generics and currency headwinds.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), LLY: 72.30 (+0.09), NVS: 103.45 (-0.62)
OncoMed Down on Phase Ib Lung Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:25PM CDT
OncoMed Pharmaceuticals Inc. (OMED) announced discouraging new data from a phase Ib study on demcizumab for first-line advanced non-small cell lung cancer.
OMED: 25.81 (-0.32), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), LLY: 72.30 (+0.09)
Lilly's ixekizumab successful in Phase 3 psoriatic arthritis trial
Seeking Alpha - at Seeking Alpha - Mon Apr 20, 8:19AM CDT
LLY: 72.30 (+0.09)
Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015
PR Newswire - Mon Apr 20, 8:00AM CDT
Eli Lilly and Company (NYSE: LLY) will present early stage data from several targeted cancer therapies, reflecting Lilly's diverse oncology pipeline, during the American Association for Cancer Research (AACR) Annual Meeting 2015, held April 18-22 in Philadelphia, Pa.
LLY: 72.30 (+0.09)
Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis
PR Newswire - Mon Apr 20, 7:00AM CDT
Eli Lilly and Company (NYSE: LLY) announced today that the investigational medicine ixekizumab was statistically superior to placebo in the treatment of patients with active psoriatic arthritis (PsA), as demonstrated by the proportion of patients achieving an ACR 20 response. ACR 20 is a standard assessment that represents a 20 percent reduction in disease signs and symptoms as defined by the American College of Rheumatology response criteria. During the 24-week, Phase 3 study, titled SPIRIT-P1, patients who were naïve to biologic disease-modifying antirheumatic drugs (bDMARD) were treated with one of two different ixekizumab dosing regimens or placebo. In both dosing regimens, ixekizumab-treated patients demonstrated significant improvements versus placebo in signs and symptoms of active PsA.
LLY: 72.30 (+0.09)
Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019
M2 - Mon Apr 20, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w97ksb/global_acquired) has announced the addition of the "Global Acquired Orphan Blood Diseases Therapeutics Market 2015-2019" report to their offering. The Global Acquired Orphan Blood Diseases Therapeutics market to grow at a CAGR of 12.29% over the period 2014-2019 Acquired orphan blood diseases are rare disorders and are characterized by the body's inability to produce a sufficient amount of RBCs. This is basically because of the improper functioning of bone marrow to produce RBCs in the blood. This leads to a decrease in platelet counts, which can eventually lead to anemia and thrombosis. This report covers the present scenario and the growth prospects of the Global Acquired Orphan Blood Diseases Therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sale of marketed drugs used in the treatment of PNH, ITP, PV, MF, and MDS. Entry into untapped markets is one of the major trends upcoming in the market. Currently, the market in many geographical locations remains untapped and provides immense opportunities for vendors to invest in the same. Companies that are pioneers in the development of drugs for acquired orphan blood diseases target physicians who prescribe patients these drugs instead of surgeries and chemotherapy. This has helped manufacturers to increase their product price. According to the report, patients diagnosed with acquired orphan blood diseases mostly rely on generics for the treatment. Side effects of these drugs are high and the treatment regimen requires high level of commitment from patients such as regular hospital visits and checkups. Further, the report states that most pharmaceutical and biotech companies invest extensively in the development of novel drugs to treat rare diseases. However, when marketing and distribution of drugs to potential consumers is taken into consideration, companies are hesitant to invest for the same. Low prevalence of orphan diseases makes it difficult for companies to locate the target population. Key Vendors - Alexion Pharmaceuticals - Amgen - Celgene - F. Hoffmann- La Roche - GlaxoSmithKline - Incyte Other Prominent Vendors - Cyclacel Pharmaceuticals - CTI Biopharma (Cell Therapeutics) - Eli Lilly - Gilead Sciences - Onconova Therapeutics - MebVax Therapeutics - Novartis - Sanofi - Shire Pharmaceuticals - S* Bio Pte For more information visit http://www.researchandmarkets.com/research/w9...l_acquired
CYCC: 0.94 (-0.03), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ALXN: 188.19 (+1.41), AMGN: 169.10 (+0.64), ONTX: 2.48 (-0.05), LLY: 72.30 (+0.09), GSK: 46.57 (-0.67), NVS: 103.45 (-0.62), CELGZ: 2.87 (+0.04)
Chasing High Dividend Growth Rates For Lower Total Returns
Kurtis Hemmerling - at Seeking Alpha - Mon Apr 20, 5:24AM CDT
RF: 9.73 (+0.15), HSY: 98.33 (+0.31), GPC: 93.02 (+0.57), CAG: 37.52 (-0.09), ED: 61.64 (+0.17), SYY: 37.63 (+0.03), RRD: 19.55 (+0.07), GWW: 243.45 (+0.44), TGT: 81.34 (+0.09), LOW: 73.07 (-0.17), BCR: 175.09 (+0.24), PFE: 34.93 (+0.04), VFC: 73.91 (-0.42), FDO: 79.25 (-0.09), MHFI: 104.25 (+0.69), MO: 52.12 (+0.02), WBA: 87.02 (-0.07), ADP: 85.31 (+0.21), ADM: 48.10 (+0.16), SIAL: 138.92 (+0.17), MRK: 57.69 (+0.03), MCD: 97.84 (+2.97), DOV: 71.89 (-0.04), CTL: 36.27 (-0.03), MMM: 164.67 (+0.67), TE: 19.40 (unch), GE: 26.91 (+0.29), BDX: 144.33 (-1.24), HBAN: 11.03 (-0.14), KMB: 111.85 (-1.30), AON: 97.20 (+0.10), CB: 99.30 (-0.44), KEY: 14.34 (+0.16), K: 63.98 (+0.12), PEP: 97.28 (+0.50), SWK: 98.11 (+1.03), JNJ: 100.43 (+0.13), AVY: 51.78 (+0.28), CMA: 46.05 (+0.62), PPG: 226.40 (-0.65), KO: 41.31 (+0.53), XEL: 34.31 (+0.03), ABT: 48.35 (+1.23), NUE: 46.82 (+0.01), SVU: 11.01 (-0.10), EMR: 58.15 (-0.07), LEG: 44.32 (unch), LLY: 72.30 (+0.09), ITW: 94.44 (+0.02), PLL: 97.75 (-0.81), USB: 42.83 (+0.33), GCI: 35.17 (-0.83), PG: 83.09 (+0.01), JCI: 51.33 (+0.30)
After Yesterday's Decline of 1.39%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Fri Apr 17, 4:23PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $71.96 to a high of $73.20. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $73.10 on volume of 4.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 72.30 (+0.09)
SmarTrend Watching for Potential Rebound in Shares of Eli Lilly After 1.39% Loss
Comtex SmarTrend(R) - Fri Apr 17, 4:22PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $71.96 to a high of $73.20. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of $73.10 on volume of 4.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 72.30 (+0.09)
Bristol-Myers to Transfer Certain Erbitux Rights to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 3:45PM CDT
Bristol-Myers announced its intention to transfer its rights to Erbitux in North America to Eli Lilly and Company.
VRX: 206.93 (-3.92), LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
Bristol-Myers Squibb Company announces transfer of full commercialisation rights to Eli Lilly and Company for Erbitux (cetuximab)
M2 - Fri Apr 17, 6:15AM CDT
Biopharmaceutical products company Bristol-Myers Squibb Company (NYSE:BMY) declared on Thursday an agreement to transfer the rights to Erbitux (cetuximab) in North America, including the US, Canada and Puerto Rico, to Eli Lilly and Company (NYSE:LLY).
LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
AstraZeneca's Onglyza Label Needs Revision per FDA Panel - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 5:04PM CDT
AstraZeneca's (AZN) Onglyza and Kombiglyze XR labels have been recommended to include new safety information as per an FDA panel.
MRK: 57.69 (+0.03), AZN: 73.35 (+0.65), AVEO: 2.04 (+0.12), LLY: 72.30 (+0.09)
Bristol-Myers transfers Erbitux to Eli Lilly in North America
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 11:53AM CDT
LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
Lilly, Bristol-Myers Squibb Restructure Erbitux(R) (cetuximab) Collaboration in North America
Business Wire - Thu Apr 16, 11:15AM CDT
Eli Lilly and Company (NYSE:LLY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have agreed to transfer rights to Erbitux(R) (cetuximab) in North America, including the U.S., Canada, and Puerto Rico, from Bristol-Myers Squibb to Lilly. Rights include, but are not limited to, full commercialization and manufacturing operational responsibilities. The companies' decision comes after a 14-year successful collaboration, which includes Lilly's wholly-owned subsidiary ImClone LLC. Bristol-Myers Squibb and Lilly will work closely to ensure a smooth transition on this important product for patients with certain advanced colorectal and head and neck cancers.
LLY: 72.30 (+0.09), BMY: 66.60 (-0.21)
